GlassScriptPhysician profile
Reetuparna Bhattacharjee
NPI 1700269461
$2,483.73
in general payments reported to CMS, 2019-2025
21 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $136 · 2021: $69.75 · 2022: $273 · 2023: $554 · 2024: $649 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $569.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.22 | 2022-2025 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $258.16 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $204.29 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $174.24 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $122.37 | 2024-2025 | |
| Portola Pharmaceuticals, LLC | $105.70 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.68 | 2023-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $88.58 | 2022-2025 | Gardasil 9, Verquvo, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $84.83 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $41.16 | 2023-2025 | Breztri |
| Exact Sciences Corporation | $31.66 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $31.17 | 2020-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $30.02 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $27.26 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $27.17 | 2025 | Aptima |
| Celgene Corporation | $19.00 | 2025 | Zeposia |
| Argenx US, INC. | $18.08 | 2024 | Vyvgart Hytrulo |
| Pfizer INC. | $17.00 | 2024 | |
| Genentech USA, INC. | $16.18 | 2025 | Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reetuparna Bhattacharjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.